Hikma Pharmaceuticals Future Growth
Future criteria checks 2/6
Hikma Pharmaceuticals is forecast to grow earnings and revenue by 18% and 4% per annum respectively. EPS is expected to grow by 18.6% per annum. Return on equity is forecast to be 18.8% in 3 years.
Key information
18.0%
Earnings growth rate
18.6%
EPS growth rate
Pharmaceuticals earnings growth | 20.7% |
Revenue growth rate | 4.0% |
Future return on equity | 18.8% |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,231 | 474 | 435 | 702 | 7 |
12/31/2025 | 3,073 | 450 | 489 | 748 | 10 |
12/31/2024 | 2,970 | 418 | 435 | 645 | 10 |
12/31/2023 | 2,875 | 190 | 404 | 608 | N/A |
9/30/2023 | 2,803 | 168 | 389 | 596 | N/A |
6/30/2023 | 2,731 | 146 | 373 | 583 | N/A |
3/31/2023 | 2,624 | 167 | 344 | 557 | N/A |
12/31/2022 | 2,517 | 188 | 314 | 530 | N/A |
9/30/2022 | 2,534 | 267 | 325 | 557 | N/A |
6/30/2022 | 2,550 | 346 | 335 | 583 | N/A |
3/31/2022 | 2,552 | 384 | 372 | 611 | N/A |
12/31/2021 | 2,553 | 421 | 409 | 638 | N/A |
9/30/2021 | 2,489 | 444 | 294 | 517 | N/A |
6/30/2021 | 2,425 | 467 | 179 | 396 | N/A |
3/31/2021 | 2,383 | 449 | 210 | 430 | N/A |
12/31/2020 | 2,341 | 431 | 240 | 464 | N/A |
9/30/2020 | 2,317 | 472 | 306 | 521 | N/A |
6/30/2020 | 2,292 | 513 | 372 | 577 | N/A |
3/31/2020 | 2,250 | 500 | 329 | 525 | N/A |
12/31/2019 | 2,207 | 486 | 286 | 472 | N/A |
9/30/2019 | 2,173 | 424 | 283 | 452 | N/A |
6/30/2019 | 2,138 | 361 | 279 | 432 | N/A |
3/31/2019 | 2,104 | 322 | 285 | 431 | N/A |
12/31/2018 | 2,070 | 282 | 291 | 430 | N/A |
9/30/2018 | 2,045 | -262 | 275 | 417 | N/A |
6/30/2018 | 2,020 | -806 | 259 | 403 | N/A |
3/31/2018 | 1,978 | -824 | 276 | 423 | N/A |
12/31/2017 | 1,936 | -843 | 292 | 443 | N/A |
9/30/2017 | 1,950 | -338 | N/A | 431 | N/A |
6/30/2017 | 1,963 | 166 | N/A | 419 | N/A |
3/31/2017 | 1,957 | 161 | N/A | 356 | N/A |
12/31/2016 | 1,950 | 155 | N/A | 293 | N/A |
9/30/2016 | 1,782 | 166 | N/A | 317 | N/A |
6/30/2016 | 1,613 | 176 | N/A | 340 | N/A |
3/31/2016 | 1,527 | 214 | N/A | 353 | N/A |
12/31/2015 | 1,440 | 252 | N/A | 366 | N/A |
9/30/2015 | 1,450 | 248 | N/A | 358 | N/A |
6/30/2015 | 1,460 | 243 | N/A | 350 | N/A |
3/31/2015 | 1,475 | 261 | N/A | 388 | N/A |
12/31/2014 | 1,489 | 278 | N/A | 425 | N/A |
9/30/2014 | 1,477 | 293 | N/A | 413 | N/A |
6/30/2014 | 1,465 | 308 | N/A | 401 | N/A |
3/31/2014 | 1,415 | 260 | N/A | 369 | N/A |
12/31/2013 | 1,365 | 212 | N/A | 337 | N/A |
9/30/2013 | 1,290 | 172 | N/A | 305 | N/A |
6/30/2013 | 1,215 | 133 | N/A | 273 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: H5P's forecast earnings growth (18% per year) is above the savings rate (0.7%).
Earnings vs Market: H5P's earnings (18% per year) are forecast to grow faster than the German market (15.4% per year).
High Growth Earnings: H5P's earnings are forecast to grow, but not significantly.
Revenue vs Market: H5P's revenue (4% per year) is forecast to grow slower than the German market (5.5% per year).
High Growth Revenue: H5P's revenue (4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: H5P's Return on Equity is forecast to be low in 3 years time (18.8%).